EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted DNA sequencing of high‐grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression

Petr Holý iD, Viktor Hlaváč iD, Karolína Šeborová iD, Simona Šůsová, Tereza Tesařová iD, Lukáš Rob, Martin Hruda, Jiří Bouda, Alena Bartáková, Marcela Mrhalová, Kateřina Kopečková, Mohammad Al Obeed Allah und 4 weitere

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34908 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Petr Holý und 15 weiteren Autor:innen. Beteiligte Einrichtung: Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Tumor Suppressor Protein p53, Drug Resistance, Neoplasm, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Czech Health Research Council, Agentura Pro Zdravotnický Výzkum České Republiky.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High‐grade serous ovarian carcinoma (HGSC) is the most common subtype of ovarian cancer and is among the most fatal gynecological malignancies worldwide, due to late diagnosis at advanced stages and frequent therapy resistance. In 47 HGSC patients, we assessed somatic and germline genetic variability of a custom panel of 144 known or suspected HGSC‐related genes by high‐coverage targeted DNA sequencing to identify the genetic determinants associated with resistance to platinum‐based therapy. In the germline, the most mutated genes were DNAH14 (17%), RAD51B (17%), CFTR (13%), BRCA1 (11%), and RAD51 (11%). Somatically, the most mutated gene was TP53 (98%), followed by CSMD1/2/3 (19/19/36%), and CFTR (23%). Results were compared with those from whole exome sequencing of a similar set of 35 HGSC patients. Somatic variants in TP53 were also validated using GENIE data of 1287 HGSC samples. Our approach showed increased prevalence of high impact somatic and germline mutations, especially those affecting splice sites of TP53 , compared to validation datasets. Furthermore, nonsense TP53 somatic mutations were negatively associated with patient survival. Elevated TP53 transcript levels were associated with platinum resistance and presence of TP53 missense mutations, while decreased TP53 levels were found in tumors carrying mutations with predicted high impact, which was confirmed in The Cancer Genome Atlas data ( n = 260). Targeted DNA sequencing of TP53 combined with transcript quantification may contribute to the concept of precision oncology of HGSC. Future studies should explore targeting the p53 pathway based on specific mutation types and co‐analyze the expression and mutational profiles of other key cancer genes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsTumor Suppressor Protein p53Drug Resistance, NeoplasmCystadenocarcinoma, SerousHumansFemaleMiddle AgedMutationAgedAdultGerm-Line MutationGene Expression Regulation, NeoplasticExome SequencingPlatinum

Stichwörter der Autor:innen

TP53biomarkersovarian carcinomaplatinum resistancetreatment response

Substanzen

Tumor Suppressor Protein p53TP53 protein, humanPlatinum

Autor:innen und Institutionen

  • Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic.
  • Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
  • Department of Gynecology and Obstetrics, Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
  • Department of Gynecology and Obstetrics, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
  • Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

ORCID-Profile: Petr Holý, Viktor Hlaváč, Karolína Šeborová, Tereza Tesařová, Pavel Souček, Radka Václavíková

Förderung

  • Czech Health Research Council
  • Agentura Pro Zdravotnický Výzkum České Republiky

Zitieren

APA

Holý, P., Hlaváč, V., Šeborová, K., Šůsová, S., Tesařová, T., Rob, L., Hruda, M., Bouda, J., Bartáková, A., Mrhalová, M., Kopečková, K., Al Obeed Allah, M., Špaček, J., Sedláková, I., Souček, P., & Václavíková, R. (2024). Targeted DNA sequencing of high‐grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression. International Journal of Cancer. https://doi.org/10.1002/ijc.34908

Vancouver

Holý P, Hlaváč V, Šeborová K, Šůsová S, Tesařová T, Rob L, et al. Targeted DNA sequencing of high‐grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression. International Journal of Cancer. 2024. doi:10.1002/ijc.34908

BibTeX
@article{Hol2024,
  author = {Holý, Petr and Hlaváč, Viktor and Šeborová, Karolína and Šůsová, Simona and Tesařová, Tereza and Rob, Lukáš and Hruda, Martin and Bouda, Jiří and Bartáková, Alena and Mrhalová, Marcela and Kopečková, Kateřina and Al Obeed Allah, Mohammad and Špaček, Jiří and Sedláková, Iva and Souček, Pavel and Václavíková, Radka},
  title = {Targeted DNA sequencing of high‐grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34908}
}
Kostenlos starten →